Upping the ante on antibodies

Nature Biotechnology

Volumn 23, Issue 9, 2005, Pages 1065-1072

  Baker, Monya ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INDUSTRIAL MANAGEMENT;

ANTE;

ANTIBODIES;

ABCIXIMAB; ADALIMUMAB; ANTIBODY; CETUXIMAB; EFALIZUMAB; FC RECEPTOR; GEMTUZUMAB OZOGAMICIN; OKT 3; ORTHOCLONE; PANITUMUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; COST BENEFIT ANALYSIS; DRUG COST; DRUG MARKETING; DRUG POTENCY; HUMAN; IMMUNE RESPONSE; MELANOMA; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; VALIDATION PROCESS;

ANTIBODIES; BINDING SITES; BIOTECHNOLOGY; CHEMISTRY, PHARMACEUTICAL; DRUG INDUSTRY; EUROPE; GENETIC ENGINEERING; HUMANS; RESEARCH SUPPORT; UNITED STATES;

EID: 27144457668     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0905-1065     Document Type: Review

References (4)

1. Evans, D. & Das, R. Monoclonal Antibodies: Evolving into a $30 Billion Market (DataMonitor, London, UK, 2005).
2. Mitchell, P. Next generation monoclonals less profitable than trailblazers? Nat. Biotechnol. 23, 906 (2005).
3. Presta, L. Antibody engineering for therapeutics. Curr. Opin. Struct. Biol. 13, 519-526 (2003).
4. Lu, D. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J. Biol. Chem. 279, 2856-2865 (2004).